Given the diversity of available testing platforms and the challenges associated within accumulating treatment experience due to the low incidence of RET fusion in NSCLC, it is crucial to standardize the screening of RET alterations and the application of RET inhibitors. Here, RET is linked to non-small cell lung carcinoma.